［1］Zheng Y, Ley S, Hu F. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications［J］. Nat Rev Endocrinol, 2018,14（2）:88-98.

［2］Yahagi K, Kolodgie F, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus［J］. Arterioscler Thromb Vasc Biol, 2017,37（2）:191-204.

［3］Shi Y, Vanhoutte P. Macroand microvascular endothelial dysfunction in diabetes［J］. J Diabetes, 2017,9（5）:434-449.

［4］King GL, Park K, Li Q. Selective insulin resistance and the development of cardiovascular diseases in diabetes: The 2015 Edwin Bierman Award Lecture［J］. Diabetes, 2016,65（6）:1462-1471.

［5］Lv R, Maehara A, Matsumura M, et al. Using optical coherence tomography and intravascular ultrasound imaging to quantify coronary plaque cap thickness and vulnerability: a pilot study［J］. Biomed Eng Online, 2020,19（1）:90.

［6］Sharma A, Coles A, Sekaran N, et al. Stress testing versus CT angiography in patients with diabetes and suspected coronary artery disease［J］. J Am Coll Cardiol, 2019,73（8）:893-902.

［7］Al Badarin FJ, Malhotra S. Diagnosis and prognosis of coronary artery disease with SPECT and PET［J］. Curr Cardiol Rep, 2019,21（7）:57.

［8］Danad I, Raijmakers P, Driessen R, et al. Comparison of coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve［J］. JAMA Cardiol, 2017,2（10）:1100-1107.

［9］De Rosa R, VasaNicotera M, Leistner D, et al. Coronary atherosclerotic plaque characteristics and cardiovascular risk factorsinsights from an optical coherence tomography study［J］. Circ J， 2017,81（8）:1165-1173.

［10］Hou J, Lv H, Jia H, et al. OCT assessment of allograft vasculopathy in heart transplant recipients［J］. JACC Cardiovasc Imaging, 2012,5（6）:662-663.

［11］Zhu L, Li N, Sun L, et al. Noncoding RNAs: The key detectors and regulators in cardiovascular disease［J］. Genomics, 2021,113:1233-1246.

［12］Dong J, Liang YZ, Zhang J, et al. Potential role of lipometabolismrelated microRNAs in peripheral blood mononuclear cells as biomarkers for coronary artery disease［J］. J Atheroscler Thromb, 2017,24（4）:430-441.

［13］Guo JF, Zhang Y, Zheng QX, et al. Association between elevated plasma microRNA223 content and severity of coronary heart disease［J］. Scand J Clin Lab Invest, 2018,78（5）:373-378.

［14］Amr KS, Abdelmawgoud H, Ali ZY, et al. Potential value of circulating microRNA126 and microRNA210 as biomarkers for type 2 diabetes with coronary artery disease［J］. Br J Biomed Sci, 2018,75（2）:82-87.

［15］Kaess BM, Preis SR, Lieb W, et al. Circulating brainderived neurotrophic factor concentrations and the risk of cardiovascular disease in the community［J］. J Am Heart Assoc, 2015,4（3）:e001544.

［16］Low JSY, Thevarajah TM, Chang SW, et al. Biosensing based on surfaceenhanced Raman spectroscopy as an emerging/nextgeneration pointofcare approach for acute myocardial infarction diagnosis［J］. Crit Rev Biotechnol, 2020,40（8）:1191-1209.

［17］Jorge J, Harford M, Villarroel M, et al. Noncontact assessment of peripheral artery haemodynamics using video infrared thermography［J］. IEEE Trans Biomed Eng,2021,68（1）:276-288.

［18］Khalil MA, Kim HK, Hoi JW, et al. Detection of peripheral arterial disease within the foot using vascular optical tomographic imaging: a clinical pilot study［J］. Eur J Vasc Endovasc Surg, 2015,49（1）:83-89.

［19］Breen PP, Gargiulo GD. Hemodynamic monitor for rapid, costeffective assessment of peripheral vascular function［A］. In: 2014 36th annual international conference of the IEEE engineering medicine and biology society［C］. New York: IEEE, 2014.

［20］Previgliano I. Assessment: transcranial doppler ultrasonography: report of the therapeutics and technology assessment subcommittee of the american academy of neurology［J］. Neurology, 2004,63（12）:2457-2458.

［21］Tian J, Chen H, Liu P, et al. Fasting apolipoprotein B48 is associated with large artery atherosclerotic stroke: a casecontrol study［J］. Sci Rep, 2019,9（1）:3729.

［22］He XW, Ke SF, Bao YY, et al. Serum levels of endocan and endoglin are associated with largeartery atherosclerotic stroke［J］. Clin Chim Acta, 2018,478:157-161.

［23］Ozaki S, Kurata M, Kumon Y, et al. Plasma thrombincleaved osteopontin as a potential biomarker of acute atherothrombotic ischemic stroke［J］. Hypertens Res, 2017,40（1）:61-66.

［24］Kurinami H, Shimamura M, Nakagami H, et al. A novel therapeutic peptide as a partial agonist of RANKL in ischemic stroke［J］. Sci Rep, 2016,6:38062.

［25］Ouerd S, IdrisKhodja N, Trindade M, et al. Endotheliumrestricted endothelin1 overexpression in type1 diabetes worsens atherosclerosis and immune cell infiltration via NOX1［J］. Cardiovasc Res,2021,117（4）:1144-1153.

［26］Camici G, Savarese G, Akhmedov A, et al. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease［J］. Eur Heart J, 2015,36（48）:3392-3403.

［27］Ahmadi A, Dabidi Roshan V, Jalali A. Coronary vasomotion and exerciseinduced adaptations in coronary artery disease patients: A systematic review and metaanalysis［J］. J Res Med Sci, 2020,25:76.

［28］Gulsin GS, Swarbrick DJ, Athithan L, et al. Effects of lowenergy diet or exercise on cardiovascular function in workingage adults with type 2 diabetes: a prospective, randomized, openlabel, blinded end point trial［J］. Diabetes Care, 2020,43（6）:1300-1310.

［29］Yu D, Tomasiewicz J, Yang S, et al. Calorierestrictioninduced insulin sensitivity is mediated by adipose mTORC2 and not required for lifespan extension［J］. Cell Rep, 2019,29（1）:236-248.

［30］Lam J, McKeague M. Dietary modulation of mitochondrial DNA damage: implications in aging and associated diseases［J］. J Nutr Biochem, 2019,63:1-10.

［31］Nowak K, Rossman M, Chonchol M, et al. Strategies for achieving healthy vascular aging［J］. Hypertension， 2018,71（3）:389-402.

［32］Kraus W, Bhapkar M, Huffman K, et al. 2 years of calorie restriction and cardiometabolic risk （CALERIE）: exploratory outcomes of a multicentre, phase 2, randomised controlled trial［J］. Lancet Diabetes Endocrinol, 2019,7（9）:673-683.

［33］Silva IVG, de Figueiredo RC, Rios DRA. Effect of different classes of antihypertensive drugs on endothelial function and inflammation［J］. Int J Mol Sci, 2019,20（14）:3458.

［34］Cameron AC, Lang NN, Touyz RM. Drug treatment of hypertension: focus on vascular health［J］. Drugs, 2016,76（16）:1529-1550.

［35］Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin Ⅱ type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension［J］. Hypertension, 2000,35:501-506.

［36］Lüscher T, Pieper M, Tendera M, et al. A randomized placebocontrolled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE Ⅱ study［J］. Eur Heart J, 2009,30（13）:1590-1597.

［37］Lee S, Chang H, Sung J, et al. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study［J］. JACC Cardiovasc Imaging, 2018,11（10）:1475-1484.

［38］Shioi A, Ikari Y. Plaque calcification during atherosclerosis progression and regression［J］. J Atheroscler Thromb, 2018,25（4）:294-303.

［39］Brili S, Tousoulis D, Antonopoulos A, et al. Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta［J］. Heart, 2012,98（4）:325-329.

［40］Bridges H, Jones A, Pollak M, et al. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria［J］. Biochem J, 2014,462（3）:475-487.

［41］Algire C, Moiseeva O, DeschênesSimard X, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage［J］. Cancer Prev Res （Phila）, 2012,5（4）:536-543.

［42］Lu Y, Wang Y, Weng T, et al. Association between metformin use and coronary artery calcification in type 2 diabetic patients［J］. J Diabetes Res, 2019,2019:9484717.

［43］Kooy A, de Jager J, Lehert P, et al. Longterm effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus［J］. Arch Intern Med, 2009,169（6）:616-625.

［44］Zilov A, Abdelaziz S, AlShammary A, et al. Mechanisms of action of metformin with special reference to cardiovascular protection［J］. Diabetes Metab Res Rev, 2019,35（7）:3173.

［45］Grnros J, Kiss A, Palmér M, et al. Arginase inhibition improves coronary microvascular function and reduces infarct size following ischaemiareperfusion in a rat model［J］. Acta Physiol （Oxf）, 2013,208（2）:172-179.

［46］Shemyakin A, Kvamees O, Rafnsson A, et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus［J］. Circulation, 2012,126（25）:2943-2950.

［47］Distelmaier K, Schrutka L, Seidl V, et al. Prooxidant HDL predicts poor outcome in patients with STelevation acute coronary syndrome［J］. Thromb Haemost, 2015,114（1）:133-138.

［48］Canesi F, Mateo V, Couchie D, et al. A thioredoxinmimetic peptide exerts potent antiinflammatory, antioxidant, and atheroprotective effects in ApoE2.Ki mice fed high fat diet［J］. Cardiovasc Res, 2019,115（2）:292-301.

［49］Domingueti CP, Dusse LM, Carvalho M, et al. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications［J］. J Diabetes Complications, 2016,30（4）:738-745.